{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:56:28Z","timestamp":1791280588405,"version":"4.1.0"},"reference-count":32,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2017,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Moderate\u2010to\u2010severe psoriasis is associated with reduced health\u2010related quality of life (\n                      <jats:styled-content style=\"fixed-case\">HRQ<\/jats:styled-content>\n                      oL). Individuals with psoriasis are at increased risk for other medical conditions, but little information quantifies the incremental burden of psoriasis\u2010associated comorbidity among European adults, and data have generally been limited to clinical samples.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      To quantify the incremental burden of cardiovascular comorbidity and psoriatic arthritis among adults with moderate\u2010to\u2010severe psoriasis in the general population of France, Germany, Italy, Spain and the United Kingdom (\n                      <jats:styled-content style=\"fixed-case\">EU<\/jats:styled-content>\n                      5).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      All measures were self\u2010reported and came from the 2010\u20132013\n                      <jats:styled-content style=\"fixed-case\">EU<\/jats:styled-content>\n                      5 National Health and Wellness Surveys (\n                      <jats:styled-content style=\"fixed-case\">NHWS<\/jats:styled-content>\n                      ). Moderate\u2010to\u2010severe psoriasis was identified by &gt;10% body surface area affected by psoriasis and\/or use of therapies for moderate\u2013severe disease. Outcomes were\n                      <jats:styled-content style=\"fixed-case\">SF<\/jats:styled-content>\n                      \u201012v2\/\n                      <jats:styled-content style=\"fixed-case\">SF<\/jats:styled-content>\n                      \u201036v2 mental and physical component summary scores (\n                      <jats:styled-content style=\"fixed-case\">MCS<\/jats:styled-content>\n                      and\n                      <jats:styled-content style=\"fixed-case\">PCS<\/jats:styled-content>\n                      , respectively),\n                      <jats:styled-content style=\"fixed-case\">SF<\/jats:styled-content>\n                      \u20106D health utility, Work Productivity and Activity Impairment (\n                      <jats:styled-content style=\"fixed-case\">WPAI<\/jats:styled-content>\n                      ) questionnaire and healthcare use in the past 6 months. Generalized linear models compared across cardiovascular comorbidity (CV) or psoriatic arthritis (PsA) groups vs. non\u2010\n                      <jats:styled-content style=\"fixed-case\">CV<\/jats:styled-content>\n                      or non\u2010PsA groups with appropriate link functions to adjust for covariates.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among moderate\u2010to\u2010severe psoriasis respondents (\n                      <jats:italic>n<\/jats:italic>\n                      = 957), 19.8% (\n                      <jats:italic>n<\/jats:italic>\n                      = 190) reported\n                      <jats:styled-content style=\"fixed-case\">CV<\/jats:styled-content>\n                      comorbidity and 12.3% (\n                      <jats:italic>n<\/jats:italic>\n                      = 118) reported PsA. After adjustment for covariates,\n                      <jats:styled-content style=\"fixed-case\">CV<\/jats:styled-content>\n                      comorbidity was associated with 3.0 points lower\n                      <jats:styled-content style=\"fixed-case\">MCS<\/jats:styled-content>\n                      , 3.4 points lower\n                      <jats:styled-content style=\"fixed-case\">PCS<\/jats:styled-content>\n                      and 0.05 points lower\n                      <jats:styled-content style=\"fixed-case\">SF<\/jats:styled-content>\n                      \u20106D (all\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.01). Likewise, they had greater mean work impairment (48% vs. 33%), more activity impairment (48% vs. 37%), and more healthcare provider visits (8.8 vs. 6.9), emergency room visits (0.65 vs. 0.31) and hospitalizations (0.61 vs. 0.22) (all\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.05). Compared to non\u2010PsA respondents, PsA respondents also had worse mean\n                      <jats:styled-content style=\"fixed-case\">MCS<\/jats:styled-content>\n                      (2.6 points),\n                      <jats:styled-content style=\"fixed-case\">PCS<\/jats:styled-content>\n                      (6.3 points) and\n                      <jats:styled-content style=\"fixed-case\">SF<\/jats:styled-content>\n                      \u20106D scores (0.07 points), and more work impairment (52% vs. 34%), activity impairment (54% vs. 38%) and healthcare provider visits (10.5 vs. 6.9) (all\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      <jats:styled-content style=\"fixed-case\">CV<\/jats:styled-content>\n                      comorbidity and PsA were associated with significant incremental burden among\n                      <jats:styled-content style=\"fixed-case\">EU<\/jats:styled-content>\n                      5 adults with moderate\u2010to\u2010severe psoriasis.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.14286","type":"journal-article","created":{"date-parts":[[2017,4,20]],"date-time":"2017-04-20T09:43:26Z","timestamp":1492681406000},"page":"1316-1323","source":"Crossref","is-referenced-by-count":20,"title":["Incremental burden of cardiovascular comorbidity and psoriatic arthritis among adults with moderate\u2010to\u2010severe psoriasis in five European countries"],"prefix":"10.1111","volume":"31","author":[{"given":"M.","family":"Augustin","sequence":"first","affiliation":[{"name":"Institute for Health Services Research in Dermatology and Nursing (IVDP) University Medical Center Hamburg\u2010Eppendorf (UKE) Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Vietri","sequence":"additional","affiliation":[{"name":"Health Outcomes Practice Kantar Health Horsham PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Tian","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation East Hanover NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Gilloteau","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,6,1]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-010-1080-1"},{"key":"e_1_2_5_3_1","unstructured":"World Health Organization.Global Report on Psoriasis.2016. URLhttp:\/\/www.who.int\/en\/(last accessed 09 Nov 2016)."},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.339"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70112-X"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/000155500300012873"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2013.860209"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12465"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.107501"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2002.01436.x"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12748"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04411.x"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2013.03.005"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1159\/000119415"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1159\/000313825"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.01.006"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205675"},{"key":"e_1_2_5_18_1","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/ddg.12643","article-title":"Early detection of comorbidity in psoriasis: recommendations of the National Conference on Healthcare in Psoriasis","volume":"13","author":"Radtke MA","year":"2015","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.2174\/1381612820666140417105323"},{"key":"e_1_2_5_20_1","first-page":"173","article-title":"Disease burden and quality of life in psoriasis patients with and without comorbid psoriatic arthritis: results from National Psoriasis Foundation panel surveys","volume":"95","author":"Edson\u2010Heredia E","year":"2015","journal-title":"Cutis"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker365"},{"key":"e_1_2_5_22_1","volume-title":"How to Score Version 2 of the SF\u201012v2\u00ae Health Survey (with a Supplement Documenting SF\u201012\u00ae Health Survey)","author":"Ware JE","year":"2002"},{"key":"e_1_2_5_23_1","unstructured":"MaruishME(Ed).New SF36v2 User Guide 3rd ed.;2011."},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000135827.18610.0d"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-004-7713-0"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199304050-00006"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.09023.x"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04576.x"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0804595"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.07.023"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.05.001"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.14286","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.14286","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.14286","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.14286","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:39:06Z","timestamp":1791279546000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.14286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,1]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["10.1111\/jdv.14286"],"URL":"https:\/\/doi.org\/10.1111\/jdv.14286","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,1]]}}}